Grail's cancer blood test faces high-stakes FDA review
A blood test designed to spot signs of multiple cancers in apparently healthy people faces its first major regulatory hurdle Wednesday as advisers to the U.S. government review how well it works.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
Also reported by 3 other outlets
- FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance qz.com
- This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval marketwatch.com
- Grail’s cancer blood test faces high-stakes FDA review winnipegfreepress.com
